Jacksonville, United States
TapImmune Inc is a biotechnology company established in 1999, based in the United States. The company is dedicated to developing immunotherapies for various cancers, focusing on targeting both tumors and metastatic disease. Their next-generation technology aims to address the limitations of previous cancer vaccine approaches and has the potential to be a potent standalone therapy or complement existing immunotherapeutics, such as checkpoint inhibitors.
TapImmune is currently progressing with two clinical stage T-cell vaccine candidates in multiple Phase II and Phase Ib/IIa clinical trials for treating ovarian and breast cancers. Notably, their ovarian cancer programs have received FDA Fast Track and Orphan Disease Designation, which signifies their promising potential. The company collaborates with prominent industry and clinical leaders, including Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca.
Their off-the-shelf vaccines are designed to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells and have a broad applicability, targeting around 80% of the population. The most recent investment received by TapImmune was a $3.10M Post-IPO Equity investment on 24 May 2018.
